1 | (CDP6038 | - | - | - | - | 1件: 46 46 |
2 | 2-CdA | 1件: Cladribine Cladribine (Synonym: 2-CdA) | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
3 | 2-CdA, 2-chloro-2'-deoxy-beta-D-adenosine | 2件: Adenosine Adenosine, Cladribine (Synonym: 2-CdA) | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 18件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
4 | 2-CdA, 2-chloro-2'-deoxy-ß-D-adenosine | 2件: Adenosine Adenosine, Cladribine (Synonym: 2-CdA) | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 18件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
5 | 2-CdA, 2-chloro-2?-deoxy-beta-D-adenosine | 2件: Adenosine Adenosine, Cladribine (Synonym: 2-CdA) | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 18件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
6 | 2-CdA, 2-chloro-2?-deoxy-ß-D-adenosine | 2件: Adenosine Adenosine, Cladribine (Synonym: 2-CdA) | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 18件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
7 | 2-CdA, 2-chloro-2’-deoxy-beta-D-adenosine | 2件: Adenosine Adenosine, Cladribine (Synonym: 2-CdA) | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 18件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
8 | 2-CdA, 2-chloro-2’-deoxy-ß-D-adenosine | 2件: Adenosine Adenosine, Cladribine (Synonym: 2-CdA) | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 18件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
9 | 2-chloro-2'-deoxy-beta-D-adenosine (2-CdA) | 2件: Adenosine Adenosine, Cladribine (Synonym: 2-CdA) | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 18件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
10 | 2-chloro-2'-deoxy-ß-D-adenosine (2-CdA) | 2件: Adenosine Adenosine, Cladribine (Synonym: 2-CdA) | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 18件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
11 | 2-chloro-2'-deoxyadenosine (2-CdA) | 1件: Cladribine Cladribine (Synonym: 2-CdA) | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
12 | 2-chloro-2’-deoxy-beta-D-adenosine (2-CdA) | 2件: Adenosine Adenosine, Cladribine (Synonym: 2-CdA) | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 18件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
13 | 2-chloro-2’-deoxy-ß-D-adenosine (2-CdA) | 2件: Adenosine Adenosine, Cladribine (Synonym: 2-CdA) | 2件: D00045
D00045
,
D01370
| 5件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3, RRM1 💬 | 18件: Alcoholism Alcoholism, Calcium signaling pathway, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nucleotide metabolism, Parkinson disease, Purine metabolism, Pyrimidine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 13 13 |
14 | 2-chloro-2’-deoxyadenosine (2-CdA) | 1件: Cladribine Cladribine (Synonym: 2-CdA) | 1件: D01370
D01370
| 1件: RRM1 RRM1 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Nucleotide metabolism, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 13 13 |
15 | Adeno-associated virus serotype 2/6 encoding human alpha-galactosidase A cDNA | 1件: Agalsidase alfa Agalsidase alfa | 1件: D02784
D02784
| 1件: GLA GLA 💬 | 6件: Galactose metabolism Galactose metabolism, Glycerolipid metabolism, Glycosphingolipid biosynthesis - globo and isoglobo series, Lysosome, Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 |
16 | ALLO-ASC-CD | - | - | - | - | 1件: 96 96 |
17 | Anti CD3 monoclonal antibody | - | - | - | - | 1件: 97 97 |
18 | Anti-CD19-CAR-T cells | - | - | - | - | 1件: 49 49 |
19 | Anti-CD20 antibody | - | - | - | - | 1件: 64 64 |
20 | Anti-CD20 B cell depletion with Truxima | - | - | - | - | 1件: 49 49 |
21 | Anti-CD20 small modular immunopharmaceutical, WYE-400087 | - | - | - | - | 1件: 46 46 |
22 | Anti-CD25 Humanized Monoclonal Antibody | - | - | - | - | 1件: 13 13 |
23 | Anti-CD28dAb | - | - | - | - | 3件: 49 49, 53, 160 |
24 | Anti-CD3 | 1件: Muromonab Muromonab (Synonym: Muromonab-CD3) | - | - | - | 2件: 96 96, 97 |
25 | Anti-CD3 Monoclonal antibody | 1件: Muromonab Muromonab (Synonym: Muromonab-CD3) | - | - | - | 2件: 96 96, 97 |
26 | Anti-CD40L | 1件: Toralizumab Toralizumab (Synonym: Anti-CD 154 human-mouse monoclonal antibody) | 1件: D06193
D06193
| 1件: CD40LG CD40LG 💬 | 14件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, Lipid and atherosclerosis, Malaria, NF-kappa B signaling pathway, Primary immunodeficiency, Systemic lupus erythematosus, T cell receptor signaling pathway, Toxoplasmosis, Viral myocarditis 💬 | 1件: 63 63 |
27 | Anti-CD40LdAb | - | - | - | - | 1件: 63 63 |
28 | Anti-CD45 | - | - | - | - | 3件: 60 60, 65, 285 |
29 | Anti-CD52 monoclonal antibody | - | - | - | - | 1件: 13 13 |
30 | AP-CD/LD | - | - | - | - | 1件: 6 6 |
31 | Assigned Interventions CD19/BCMA CAR T-cells | - | - | - | - | 3件: 49 49, 51, 53 |
32 | Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene | - | - | - | - | 1件: 65 65 |
33 | AUTOLOGOUS CD34+ CELLS TRANSDUCED EX-VIVO WITH THE PCCLCHIMGP91/VSVG LENTIVIRAL VECTOR | - | - | - | - | 1件: 65 65 |
34 | AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH A LENTIVIRAL VECTOR CONTAINING THE HUMAN SGSH GENE | - | - | - | - | 1件: 19 19 |
35 | Autologous CD34+ cells transduced with a lentiviral vector encoding the ARSA cDNA | - | - | - | - | 1件: 19 19 |
36 | AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH LENTI-D VECTOR ENCODING ABCD1 CDNA | - | - | - | - | 1件: 20 20 |
37 | Autologous CD34+ cells transduced with the Lentiviral vector containing the human Wiskott Aldrich Sy | - | - | - | - | 1件: 65 65 |
38 | Autologous CD34+ cells transduced with WASP lentiviral vector | - | - | - | - | 1件: 65 65 |
39 | Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human Wiskott Aldrich Syndrome (WAS) cDNA sequence | - | - | - | - | 1件: 65 65 |
40 | Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII | - | - | - | - | 1件: 19 19 |
41 | Autologous CD34+ HSCs transduced ex vivo with EFS lentiviral vector encoding for the human ADA gene | - | - | - | - | 1件: 65 65 |
42 | AUTOLOGOUS CD34+CELLS TRANSDUCED WITH THE W1.6_HWASP_WPRE (VSVG) LENTIVIRAL VECTOR | - | - | - | - | 1件: 65 65 |
43 | Autologous CD34-selected peripheral blood stem cells transplant | - | - | - | - | 1件: 96 96 |
44 | Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope | - | - | - | - | 1件: 13 13 |
45 | Autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA | - | - | - | - | 1件: 20 20 |
46 | Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells | - | - | - | - | 1件: 51 51 |
47 | BARDOXOLONE METHYL, CDDO-Me, CDDO-Methyl Ester, NSC 713200, Chemical Name: Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester | 2件: Bardoxolone Bardoxolone, Bardoxolone methyl | 2件: D09584
D09584
,
D09585
| - | - | 1件: 86 86 |
48 | Biologic: IC14 (monoclonal antibody against human CD14) | - | - | - | - | 1件: 2 2 |
49 | Blinded CDCA 250 mg TID | 1件: Chenodeoxycholic acid Chenodeoxycholic acid (Synonym: CDCA) | 1件: D00163
D00163
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 263 263 |
50 | BT061 (CD4 monoclonal antibody) | - | - | - | - | 1件: 46 46 |
51 | CARBIDOPA (CD) | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
52 | CD | - | - | - | - | 8件: 6 6, 13, 46, 51, 63, 96, 97, 265 |
53 | CD-4 guided therapy interruption | - | - | - | - | 1件: 265 265 |
54 | CD-C-Food | - | - | - | - | 1件: 96 96 |
55 | CD-LD CR | - | - | - | - | 1件: 6 6 |
56 | CD-LD IR | - | - | - | - | 1件: 6 6 |
57 | CD19-directed humanised afucosylated monoclonal antibody | - | - | - | - | 1件: 11 11 |
58 | CD19/BCMA CAR T-cells | - | - | - | - | 2件: 16 16, 61 |
59 | CD3/CD19 depleted leukocytes | - | - | - | - | 1件: 284 284 |
60 | CD3/CD19 neg allogeneic BMT | - | - | - | - | 1件: 65 65 |
61 | CD3/CD19 negative allogeneic hematopoietic stem cells | - | - | - | - | 1件: 65 65 |
62 | CD3/CD19 negative hematopoietic stem cells | - | - | - | - | 1件: 85 85 |
63 | CD34 selected autologous hematopoietic cells | - | - | - | - | 1件: 51 51 |
64 | CD34 Stem Cell Selection Therapy | - | - | - | - | 3件: 60 60, 65, 284 |
65 | CD34+ | - | - | - | - | 1件: 65 65 |
66 | CD34+ CELLS | - | - | - | - | 1件: 285 285 |
67 | CD34+ cells transduced with ADA retrovir | - | - | - | - | 1件: 65 65 |
68 | CD34+ enriched, T Cell Depleted donor stem cell product | - | - | - | - | 1件: 326 326 |
69 | CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1a-h?c-OPT | - | - | - | - | 1件: 65 65 |
70 | CD34+ selected cells | - | - | - | - | 1件: 285 285 |
71 | CD34+CELLS | - | - | - | - | 2件: 65 65, 285 |
72 | CD34+SC | - | - | - | - | 1件: 51 51 |
73 | CD45RA depleted leukocytes | - | - | - | - | 1件: 284 284 |
74 | CD62L- Tem | - | - | - | - | 1件: 60 60 |
75 | CD7 CAR T-cells | - | - | - | - | 3件: 50 50, 96, 97 |
76 | CDCA | 1件: Chenodeoxycholic acid Chenodeoxycholic acid (Synonym: CDCA) | 1件: D00163
D00163
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 263 263 |
77 | CDCA Weight-Based Dose TID | 1件: Chenodeoxycholic acid Chenodeoxycholic acid (Synonym: CDCA) | 1件: D00163
D00163
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 263 263 |
78 | CDED+PEN+dairy products | - | - | - | - | 1件: 96 96 |
79 | CDMARD | - | - | - | - | 1件: 46 46 |
80 | CDNF | - | - | - | - | 1件: 6 6 |
81 | CDP3194 | - | - | - | - | 1件: 49 49 |
82 | CDP323 | 1件: CDP323 CDP323 | - | - | - | 1件: 13 13 |
83 | CDP6038 | - | - | - | - | 2件: 46 46, 96 |
84 | CDP6038 (olokizumab) | 1件: Olokizumab Olokizumab | 1件: D12487
D12487
| 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 |
85 | CDP7657 | - | - | - | - | 1件: 49 49 |
86 | CDP870 | - | - | - | - | 3件: 46 46, 96, 271 |
87 | CDP870 100mg | - | - | - | - | 1件: 46 46 |
88 | CDP870 200mg | - | - | - | - | 1件: 46 46 |
89 | CDP870 400mg | - | - | - | - | 1件: 46 46 |
90 | CDP870 Fab'-PEG | - | - | - | - | 1件: 46 46 |
91 | CDX | - | - | - | - | 2件: 222 222, 240 |
92 | CDX 6114 | - | - | - | - | 1件: 240 240 |
93 | CDX-1135 | - | - | - | - | 1件: 222 222 |
94 | CDZ173 | - | - | - | - | 2件: 53 53, 65 |
95 | Cellule CD34+ autologhe trasdotte con IDUA LV codificante per il cDNA dell'alfa-L-iduronidasi | - | - | - | - | 1件: 19 19 |
96 | Certolizumab pegol (CDP870) | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 96 |
97 | Certolizumab pegol (CDP870, CZP) | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 |
98 | Certolizumab pegol (CDP870, tradename Cimzia) | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
99 | Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg) | 1件: Certolizumab pegol Certolizumab pegol | 1件: D03441
D03441
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
100 | Chimeric human/mouse anti-CD-20 monoclonal antibody | - | - | - | - | 1件: 46 46 |
101 | CHX A-DTPA anti-CD66 antibody | 1件: Pentetic acid Pentetic acid | 1件: D05422
D05422
| - | - | 1件: 28 28 |
102 | CHX-A-DTPA-Anti-CD66 | 1件: Pentetic acid Pentetic acid | 1件: D05422
D05422
| - | - | 1件: 28 28 |
103 | Combination of a single dose anti-CD20 antibody and bortezomib | 1件: Bortezomib Bortezomib | 1件: D03150
D03150
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 61 61 |
104 | Crohn's disease exclusion diet (CDED) | - | - | - | - | 1件: 96 96 |
105 | CRYOPRESERVED AUTOLOGOUS CD34+ CELLS TRANSDUCED WITH A LENTIVIRAL VECTOR CONTAINING HUMAN SGSH GENE | - | - | - | - | 1件: 19 19 |
106 | Cryopreserved EFS-ADA LV transduced patient CD34+ cells | - | - | - | - | 1件: 65 65 |
107 | Cryopreserved G2SCID lentiviral vector transduced patient CD34+ cells | - | - | - | - | 1件: 65 65 |
108 | Cytolytic CD4+ T cells | - | - | - | - | 1件: 13 13 |
109 | Cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant | - | - | - | - | 1件: 62 62 |
110 | Daclizumab (Anti-CD25 Humanized Monoclonal Antibody) | 1件: Daclizumab Daclizumab | 1件: D03639
D03639
| 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
111 | Depletion in CD45RA graft donor | - | - | - | - | 1件: 65 65 |
112 | Depletion of CD3/CD19 in an autologous stem cell transplant | - | - | - | - | 2件: 49 49, 51 |
113 | Duodopa LD/CD 20/5 mg/mL | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
114 | EF1aS-ADA lentiviral vector gene modified autologous CD34+ cells | - | - | - | - | 1件: 65 65 |
115 | EF1aS-ADA lentiviral vector transduced patient CD34+ cells | - | - | - | - | 1件: 65 65 |
116 | Engineered humanized monoclonal anti-human CD19 antibody. | - | - | - | - | 1件: 46 46 |
117 | Engineered humanized monoclonal anti-human CD19 antibody. Lot Numbers: 1-FIN-1588 (9.6mg/ml) | - | - | - | - | 1件: 46 46 |
118 | ER CD-LD | - | - | - | - | 1件: 6 6 |
119 | Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector | - | - | - | - | 1件: 65 65 |
120 | Ex-vivo expanded autologous human keratinocytes suspension containing epidermal stem cells genetically modified with a gamma-retroviral (rv) vector expressing the full-length LAMB3 cDNA. | - | - | - | - | 1件: 36 36 |
121 | Fc- and CDR-modified humanised monoclonal antibody against C5 | - | - | - | - | 3件: 11 11, 62, 109 |
122 | Frozen autologous CD34+ hematopoietic stem and progenitor cells genetically modified with the lentiviral vector IDUA LV, encoding for the a-L-iduronidase cDNA, in their final formulation medium. | - | - | - | - | 1件: 19 19 |
123 | G1XCGD transduced CD34+ cells | - | - | - | - | 1件: 65 65 |
124 | Gene-Transduced Autologous CD34+ Stem Cells | - | - | - | - | 1件: 65 65 |
125 | GSK2018682 CD2 Capsule | - | - | - | - | 1件: 13 13 |
126 | GSK2018682 CD3 micronised Tablet | - | - | - | - | 1件: 13 13 |
127 | GSK2018682 CD3 non-micronised Tablet | - | - | - | - | 1件: 13 13 |
128 | GSK2018682 CD3 non-micronised Tablet in fed state | - | - | - | - | 1件: 13 13 |
129 | Human glucocerebrosidase cDNA | - | - | - | - | 1件: 19 19 |
130 | Human IgG4 monoclonal antibody against CD40 | - | - | - | - | 1件: 46 46 |
131 | Human monoclonal antibody directed against CD20 on B-cells | - | - | - | - | 1件: 46 46 |
132 | Humanised anti-CD 20 antibody | - | - | - | - | 1件: 46 46 |
133 | Humanised anti-CD4 IgG1 monoclonal | - | - | - | - | 1件: 46 46 |
134 | Humanized recombinant IgG4 monoclonal antibody against CD-127 | - | - | - | - | 1件: 97 97 |
135 | HuMax-CD20 | 1件: Ofatumumab Ofatumumab (Synonym: HuMax-CD20) | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 2件: 13 13, 46 |
136 | HUMAX-CD38 | - | - | - | - | 2件: 28 28, 63 |
137 | HuMax-CD38, 3003-005 | - | - | - | - | 1件: 28 28 |
138 | HuMax-CD4 | 1件: Zanolimumab Zanolimumab (Synonym: Humax-cd4) | 1件: D06356
D06356
| 1件: CD4 CD4 💬 | 14件: Antigen processing and presentation Antigen processing and presentation, Cell adhesion molecules, Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral life cycle - HIV-1, Virion - Human immunodeficiency virus, Yersinia infection 💬 | 1件: 46 46 |
139 | Indium 111-radiolabelled anti-CD66 | 1件: Indium Indium | - | - | - | 1件: 28 28 |
140 | Indium 111 labelled Anti-CD66 | 1件: Indium Indium | - | - | - | 1件: 28 28 |
141 | INEBILIZUMAB (Synonym: Inebilizumab-cdon) | 1件: Inebilizumab Inebilizumab (Synonym: inebilizumab-cdon) | 1件: D11757
D11757
(Name: Inebilizumab-cdon) | 1件: CD19 CD19 💬 | 5件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬 | 4件: 11 11, 13, 51, 300 |
142 | Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) | - | - | - | - | 1件: 65 65 |
143 | Infusion of autologous EFS-ADA LV CD34+ cells | - | - | - | - | 1件: 65 65 |
144 | Intravitreal autologous CD34+ cells | - | - | - | - | 1件: 90 90 |
145 | IPX203 ER CD-LD | - | - | - | - | 1件: 6 6 |
146 | IR CD-LD | - | - | - | - | 1件: 6 6 |
147 | IR CD-LD (carbidopa-levodopa) tablets | 2件: Carbidopa Carbidopa, Levodopa | 2件: D00059
D00059
,
D00558
| 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
148 | IR LD / CD | - | - | - | - | 1件: 6 6 |
149 | IR LD/CD | - | - | - | - | 1件: 6 6 |
150 | LD/CD | - | - | - | - | 1件: 6 6 |
151 | Lentiviral vector transduced CD34+ cells | - | - | - | - | 1件: 65 65 |
152 | Levodopa/Carbidopa (LD/CD) | 2件: Carbidopa Carbidopa, Levodopa | 2件: D00059
D00059
,
D00558
| 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
153 | Minibody against CD8 conjugated to desferrioxamine labeled with zirconium Zr 89 | 1件: Deferoxamine Deferoxamine | 1件: D03670
D03670
| - | - | 2件: 51 51, 53 |
154 | Muromonab-CD3 | 1件: Muromonab Muromonab (Synonym: Muromonab-CD3) | - | - | - | 1件: 60 60 |
155 | NI-0401 (anti-CD3 mAB) | 1件: Muromonab Muromonab (Synonym: Muromonab-CD3) | - | - | - | 1件: 96 96 |
156 | ONO-2160/CD | - | - | - | - | 1件: 6 6 |
157 | Open-Label CDCA 250 mg TID | 1件: Chenodeoxycholic acid Chenodeoxycholic acid (Synonym: CDCA) | 1件: D00163
D00163
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 263 263 |
158 | PCCLchimGp91s lentiviral vector transduced CD34+ cells infusion | - | - | - | - | 1件: 65 65 |
159 | Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells | - | - | - | - | 1件: 65 65 |
160 | Phase1 : CDED/Modulen™IBD® + Maintenance therapy | - | - | - | - | 1件: 96 96 |
161 | Plerixafor mobilization of autologous CD117 stem cells | 1件: Plerixafor Plerixafor | 1件: D08971
D08971
| 1件: CXCR4 CXCR4 💬 | 14件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral life cycle - HIV-1, Viral protein interaction with cytokine and cytokine receptor, Virion - Human immunodeficiency virus 💬 | 1件: 299 299 |
162 | RAG1 LV CD34+ cells | - | - | - | - | 1件: 65 65 |
163 | Recombinant Adeno-associated virus 2/6 vector encoding the cDNA for human alpha galactosidase A | - | - | - | - | 1件: 19 19 |
164 | Recombinant humanized anti-CD20 monoclonal antibody | - | - | - | - | 1件: 13 13 |
165 | Rescue Medication CDCA 250 mg TID | 1件: Chenodeoxycholic acid Chenodeoxycholic acid (Synonym: CDCA) | 1件: D00163
D00163
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 263 263 |
166 | Retroviral SF71-gp91phox transduced CD34+ cells | - | - | - | - | 1件: 65 65 |
167 | Rituximab (anti-CD20) | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 53 53 |
168 | Routine Treatment of CD | - | - | - | - | 1件: 96 96 |
169 | Semi continuous intra-oral administration of LD/CD | - | - | - | - | 1件: 6 6 |
170 | Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre | - | - | - | - | 1件: 65 65 |
171 | Standard LD/CD | - | - | - | - | 1件: 6 6 |
172 | Suspension of autologous CD34+cells transduced with the G1XCGD viral vector | - | - | - | - | 1件: 65 65 |
173 | T-Cell Depleted & CD34+Select/w/StemCell Enriched Product | - | - | - | - | 1件: 65 65 |
174 | TL011, anti CD20, for the treatment of rheumatoid arthritis | - | - | - | - | 1件: 46 46 |
175 | TPO-RAs combining anti-CD 20 monoclonal antibody | - | - | - | - | 1件: 63 63 |
176 | Transduced CD34+ Cells | - | - | - | - | 1件: 285 285 |
177 | Transduced CD34+ hematopoietic stem cell | - | - | - | - | 2件: 19 19, 20 |
178 | Transduced patient CD34+ cells | - | - | - | - | 1件: 65 65 |
179 | Yttrium-90 radiolabelled anti-CD66 antibody | 1件: Yttrium Y-90 Yttrium Y-90 | - | - | - | 1件: 28 28 |
180 | Yttrium90 radiolabelled antiCD66 | 1件: Yttrium Y-90 Yttrium Y-90 | - | - | - | 1件: 28 28 |